Sural sensory action potential identifies diabetic peripheral neuropathy response to therapy

Aaron I. Vinik, Vera Bril, William J Litchy, Karen L. Price, Edward J. Bastyr

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Identifying patients with diabetic peripheral neuropathy (DPN) amenable to therapy is a challenge. To determine whether the amplitude of the sural sensory nerve action potential (sural SNAP) reflects the severity of DPN, an analysis was performed on 205 patients with DPN, identified by an abnormal vibration detection threshold (VDT), who were enrolled in a multinational clinical trial investigating ruboxistaurin (RBX) mesylate. Nerve conduction velocity and response amplitude and latency were measured and compared. VDT was significantly lower in those with preserved sural SNAPs (n = 128) than in those in whom they were absent (n = 77; 21.5 vs. 22.7 JND units, P = 0.002). Thus, preserved sural SNAP denoted less severe DPN. Logistic regression analyses evaluating baseline characteristics, HbA1c, and baseline symptom scores identified only DPN duration as a factor that might contribute to the presence of sural SNAP (P = 0.004; OR = 0.896). For patients with abnormal VDT, preserved sural SNAP identifies a patient population with less severe DPN who may respond to therapeutic intervention in clinical trials.

Original languageEnglish (US)
Pages (from-to)619-625
Number of pages7
JournalMuscle and Nerve
Volume32
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Diabetic Neuropathies
Peripheral Nervous System Diseases
Action Potentials
Sural Nerve
Vibration
ruboxistaurin
Therapeutics
Clinical Trials
Mesylates
Neural Conduction
Reaction Time
sural
Logistic Models
Regression Analysis
Population

Keywords

  • DPN, diabetic peripheral neuropathy
  • PKC β, protein kinase C β
  • Sural SNAP, sural sensory nerve action potential
  • VDT, vibration detection threshold
  • VP, vibration perception

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Sural sensory action potential identifies diabetic peripheral neuropathy response to therapy. / Vinik, Aaron I.; Bril, Vera; Litchy, William J; Price, Karen L.; Bastyr, Edward J.

In: Muscle and Nerve, Vol. 32, No. 5, 11.2005, p. 619-625.

Research output: Contribution to journalArticle

Vinik, Aaron I. ; Bril, Vera ; Litchy, William J ; Price, Karen L. ; Bastyr, Edward J. / Sural sensory action potential identifies diabetic peripheral neuropathy response to therapy. In: Muscle and Nerve. 2005 ; Vol. 32, No. 5. pp. 619-625.
@article{887dd893a3c04afda0a22f8a9f97fa1a,
title = "Sural sensory action potential identifies diabetic peripheral neuropathy response to therapy",
abstract = "Identifying patients with diabetic peripheral neuropathy (DPN) amenable to therapy is a challenge. To determine whether the amplitude of the sural sensory nerve action potential (sural SNAP) reflects the severity of DPN, an analysis was performed on 205 patients with DPN, identified by an abnormal vibration detection threshold (VDT), who were enrolled in a multinational clinical trial investigating ruboxistaurin (RBX) mesylate. Nerve conduction velocity and response amplitude and latency were measured and compared. VDT was significantly lower in those with preserved sural SNAPs (n = 128) than in those in whom they were absent (n = 77; 21.5 vs. 22.7 JND units, P = 0.002). Thus, preserved sural SNAP denoted less severe DPN. Logistic regression analyses evaluating baseline characteristics, HbA1c, and baseline symptom scores identified only DPN duration as a factor that might contribute to the presence of sural SNAP (P = 0.004; OR = 0.896). For patients with abnormal VDT, preserved sural SNAP identifies a patient population with less severe DPN who may respond to therapeutic intervention in clinical trials.",
keywords = "DPN, diabetic peripheral neuropathy, PKC β, protein kinase C β, Sural SNAP, sural sensory nerve action potential, VDT, vibration detection threshold, VP, vibration perception",
author = "Vinik, {Aaron I.} and Vera Bril and Litchy, {William J} and Price, {Karen L.} and Bastyr, {Edward J.}",
year = "2005",
month = "11",
doi = "10.1002/mus.20423",
language = "English (US)",
volume = "32",
pages = "619--625",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Sural sensory action potential identifies diabetic peripheral neuropathy response to therapy

AU - Vinik, Aaron I.

AU - Bril, Vera

AU - Litchy, William J

AU - Price, Karen L.

AU - Bastyr, Edward J.

PY - 2005/11

Y1 - 2005/11

N2 - Identifying patients with diabetic peripheral neuropathy (DPN) amenable to therapy is a challenge. To determine whether the amplitude of the sural sensory nerve action potential (sural SNAP) reflects the severity of DPN, an analysis was performed on 205 patients with DPN, identified by an abnormal vibration detection threshold (VDT), who were enrolled in a multinational clinical trial investigating ruboxistaurin (RBX) mesylate. Nerve conduction velocity and response amplitude and latency were measured and compared. VDT was significantly lower in those with preserved sural SNAPs (n = 128) than in those in whom they were absent (n = 77; 21.5 vs. 22.7 JND units, P = 0.002). Thus, preserved sural SNAP denoted less severe DPN. Logistic regression analyses evaluating baseline characteristics, HbA1c, and baseline symptom scores identified only DPN duration as a factor that might contribute to the presence of sural SNAP (P = 0.004; OR = 0.896). For patients with abnormal VDT, preserved sural SNAP identifies a patient population with less severe DPN who may respond to therapeutic intervention in clinical trials.

AB - Identifying patients with diabetic peripheral neuropathy (DPN) amenable to therapy is a challenge. To determine whether the amplitude of the sural sensory nerve action potential (sural SNAP) reflects the severity of DPN, an analysis was performed on 205 patients with DPN, identified by an abnormal vibration detection threshold (VDT), who were enrolled in a multinational clinical trial investigating ruboxistaurin (RBX) mesylate. Nerve conduction velocity and response amplitude and latency were measured and compared. VDT was significantly lower in those with preserved sural SNAPs (n = 128) than in those in whom they were absent (n = 77; 21.5 vs. 22.7 JND units, P = 0.002). Thus, preserved sural SNAP denoted less severe DPN. Logistic regression analyses evaluating baseline characteristics, HbA1c, and baseline symptom scores identified only DPN duration as a factor that might contribute to the presence of sural SNAP (P = 0.004; OR = 0.896). For patients with abnormal VDT, preserved sural SNAP identifies a patient population with less severe DPN who may respond to therapeutic intervention in clinical trials.

KW - DPN, diabetic peripheral neuropathy

KW - PKC β, protein kinase C β

KW - Sural SNAP, sural sensory nerve action potential

KW - VDT, vibration detection threshold

KW - VP, vibration perception

UR - http://www.scopus.com/inward/record.url?scp=27144477722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144477722&partnerID=8YFLogxK

U2 - 10.1002/mus.20423

DO - 10.1002/mus.20423

M3 - Article

VL - 32

SP - 619

EP - 625

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 5

ER -